$アーマタ ファーマシューティカルズ(ARMP.US)$Armata has shown a rapid enrollment rate in the Phase 2a portion of the diSArm study, which tests AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Furthermore, the company is making strides in the Phase 2 Tailwind study of AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB) patients with Pseudomonas aeruginosa lung infections. The second reason for is Armata’s diligence in preparing for future studies. The company i...
アーマタ ファーマシューティカルズに関するコメント
The second reason for is Armata’s diligence in preparing for future studies. The company i...
$エヌエヌ(NNBR.US)$ AH up 12% may look for lower entry or risk management will help
まだコメントはありません